昆药集团

Kunyao Group is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of natural plant-based medicines and Traditional Chinese Medicine (TCM). Founded in 1951 and headquartered in Kunming, the company is globally recognized for its pioneering work in artemisinin-based antimalarial drugs and its extensive portfolio of Panax notoginseng-derived treatments for cardiovascular and cerebrovascular diseases. Following its acquisition by China Resources Sanjiu, Kunyao has strategically focused on the Sanqi (Panax notoginseng) industry chain and elderly healthcare. Its business spans pharmaceutical manufacturing, commercial distribution, and international trade, with a strong presence in both domestic and global markets. The company's flagship product, Xuesaitong, is a market leader in the treatment of cardio-cerebrovascular conditions.